Xiao Nan, Yu Kailin, Yu Shaojun, Wu Jianjun, Wang Jian, Shan Siyang, Zheng Shuchun, Wang Liuhong, Wang Jianwei, Peng Shuyou
Department of Surgical Oncology, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, 310009, China.
Department of Radiology and Intervention, Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, China.
World J Surg Oncol. 2017 Aug 3;15(1):148. doi: 10.1186/s12957-017-1212-6.
For colorectal liver metastasis (CRLM) patients, hepatic resection is currently the sole cure offering the chance of long-term survival. Tumor shrinkage and planned liver remnant hypertrophy are the two key strategies for conversion of initially unresectable CRLM. First conducted in 2012, associated liver partition and portal vein ligation for staged hepatectomy (ALPPS) allows rapid liver growth. As a means to induce hypertrophy, portal vein embolization (PVE) has been widely applied before extending hepatectomy. Recently, Peng et al. present a new approach of terminal branches portal vein embolization (TBPVE), offering an efficient way to amplify FLR and making chances for surgery in 2 weeks.
We reported a 61-year-old woman with synchronous hepatic metastasized carcinoma of the colon sigmoideum underwent TBPVE after 6 cycles of neoadjuvant therapy in order to perform a planned right trisectionectomy. Rapid liver remnant hypertrophy and remarkable tumor shrinkage were achieved, and laparoscopic sigmoidectomy and right trisectionectomy were successfully performed. The postsurgical course was uneventful and 7 months of recurrence-free survival have been witnessed.
The dual tactics of tumor shrinkage and planned rapid liver remnant hypertrophy will make concerted efforts to further increase the clinical candidacy for curative resection, which are valuable for further investigation.
对于结直肠癌肝转移(CRLM)患者,肝切除是目前唯一能提供长期生存机会的治愈方法。肿瘤缩小和计划中的肝残余肥大是将最初不可切除的CRLM转化为可切除的两个关键策略。2012年首次开展的联合肝脏分隔和门静脉结扎分期肝切除术(ALPPS)可使肝脏快速生长。作为诱导肥大的一种手段,门静脉栓塞术(PVE)在扩大肝切除术之前已被广泛应用。最近,彭等人提出了一种终末分支门静脉栓塞术(TBPVE)的新方法,为扩大未来肝残余(FLR)提供了一种有效途径,并为在2周内进行手术创造了机会。
我们报告了一名61岁患有乙状结肠同步肝转移癌的女性患者,在接受6个周期新辅助治疗后接受了TBPVE,以便进行计划中的右三叶切除术。实现了快速的肝残余肥大和显著的肿瘤缩小,并成功进行了腹腔镜乙状结肠切除术和右三叶切除术。术后过程顺利,已观察到7个月无复发生存期。
肿瘤缩小和计划中的快速肝残余肥大这两种策略将共同努力进一步增加根治性切除的临床候选资格,这对于进一步研究具有重要价值。